CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenues:
Total revenue	$ 1,455	$ 2,398
Costs and expenses:
Cost of revenue	506	809
Research and development	11,584	9,845
General and administrative	6,139	6,844
Licensing	1,010	1,031
Revaluation of contingent consideration	300	2,800
Total costs and expenses	19,539	21,329
Loss from operations	(18,084)	(18,931)
Other income:
Interest income	2,166	1,990
Non-cash royalty income	833
Total other income	2,999	1,990
Net loss	$ (15,085)	$ (16,941)
Net loss per share, basic	$ (0.12)	$ (0.24)
Net loss per share, diluted	$ (0.12)	$ (0.24)
Weighted average common shares outstanding, basic	122,390,303	71,074,858
Weighted average common shares outstanding, diluted	122,390,303	71,074,858
Other comprehensive income:
Unrealized gain on marketable securities, net of tax of $0	$ 337	$ (258)
Total other comprehensive income (loss)	337	(258)
Comprehensive loss	(14,748)	(17,199)
Contract research
Revenues:
Total revenue	445	657
Licensing
Revenues:
Total revenue	$ 1,010	$ 1,741